title: [Treatment of brain metastasis from ovarian cancer].
abstract: Systemic metastases from ovarian carcinoma are frequent, but they seldom affect the central nervous system. We present here the case of a patient treated for an ovarian cancer by surgery and chemotherapy. Three months after the end of chemotherapy, the patient developed cerebral metastases from ovarian carcinoma (CMOC) treated by iterative surgery and and whole brain irradiation. As the frequency of solitary cerebral metastasis of ovarian cancer is higher than with other cancers, it is likely that they behave slightly differently. Literature analysis reveals an increase in the incidence of CMOC since the middle of the nineties. CMOC can occur during or after adjuvant chemotherapy and the best management strategies to better define determinants of survival for patients are not well known. It appears that a better outcome of CMOC may be obtained by an aggressive treatment, if possible, including surgery, radiotherapy, and chemotherapy. Taking into account the increase in the incidence of the CMOC and their early occurrence, some authors have proposed a prophylactic brain radiotherapy in patients who receive adjuvant chemotherapy.
authors.affiliation: Département de radiothérapie, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189, Nice, France. pierre-yves.bondiau@cal.nice.fnclcc.fr <pierre-yves.bondiau@cal.nice.fnclcc.fr>
authors.forename: P-Y
authors.initials: PY
authors.lastname: Bondiau
authors.forename: R
authors.initials: R
authors.lastname: Largillier
authors.forename: C
authors.initials: C
authors.lastname: Foa
authors.forename: D
authors.initials: D
authors.lastname: Rasendrarijao
authors.forename: M
authors.initials: M
authors.lastname: Frenay
authors.forename: J-P
authors.initials: JP
authors.lastname: Gérard
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000150:complications / Q000175:diagnosis / Q000556:secondary* / Q000628:therapy*; D018394:CA-125 Antigen / Q000097:blood; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003399:Craniotomy; D018293:Cystadenoma, Serous / Q000150:complications / Q000175:diagnosis / Q000556:secondary* / Q000628:therapy*; D005260:Female; D005602:France / Q000453:epidemiology; D006261:Headache / Q000209:etiology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008796:Metrorrhagia / Q000209:etiology; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000473:pathology*; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D018394:CA-125 Antigen; D017239:Paclitaxel; D002945:Cisplatin